Alisertib (MLN8237)

Name: Alisertib (MLN8237)
Brand: Selleck Chemicals
SKU: S1133
Rating: 5 (203 reviews)

For research use only.

Catalog No.S1133

203 publications

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Alisertib induces cell cycle arrest, apoptosis and autophagy. Phase 3.

Selleck's Alisertib (MLN8237) has been cited by 203 publications

Nature, 2019, 574(7777):268-272

PubMed: 31578521 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Med, 2016, 22(7):744-53

PubMed: 27213815 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Oncogene, 2020, 16

PubMed: 32300176 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32235770 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Mol Cancer Res, 2020, 8

PubMed: 32269073 ( click the link to review the publication )

J Cancer, 2020, 11(8):2241-2251

PubMed: 32127951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3485

PubMed: 31375684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5566

PubMed: 31804482 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2208

PubMed: 31101817 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3430-3442

PubMed: 30755439 ( click the link to review the publication )

Dev Cell, 2019, 50(3):355-366e6

PubMed: 31303441 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )
Cell Rep, 2019, 26(2):293-301e7

PubMed: 30625311 ( click the link to review the publication )

Oncogene, 2019, 38(1):73-87

PubMed: 30082913 ( click the link to review the publication )

EBioMedicine, 2019, 41:120-133

PubMed: 30799199 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):881

PubMed: 31754113 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):606

PubMed: 31406104 ( click the link to review the publication )

FASEB J, 2019, 33(4):4866-4882

PubMed: 30596512 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.003

PubMed: 31257184 ( click the link to review the publication )

Curr Biol, 2019, 29(21):3563-3578

PubMed: 31668617 ( click the link to review the publication )

PLoS Negl Trop Dis, 2019, 13(5):e0007425

PubMed: 31095613 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2211

PubMed: 30778113 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2019, 41(6):e359-e370

PubMed: 30702467 ( click the link to review the publication )

Target Oncol, 2019, 14(5):563-575

PubMed: 31429028 ( click the link to review the publication )

Oncotarget, 2019, 10(17):1649-1659

PubMed: 30899434 ( click the link to review the publication )

Blood Adv, 2019, 3(21):3214-3227

PubMed: 31698452 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Curr Biol, 2018, 28(21):3458-3468e5

PubMed: 30415701 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6594-6610

PubMed: 30181387 ( click the link to review the publication )

Elife, 2018, doi: 107554/eLife38111

PubMed: 30070631 ( click the link to review the publication )

Thyroid, 2018, doi: 101089/thy20180183

PubMed: 30226440 ( click the link to review the publication )
Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Oncogene, 2018, 37(22):2921-2935

PubMed: 29515234 ( click the link to review the publication )

Oncogene, 2018, 37(4):502-511

PubMed: 28967900 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):781

PubMed: 30013101 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2575-2585

PubMed: 30266802 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

Mol Pharm, 2018, 15(8):3046-3059

PubMed: 29863884 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Apoptosis, 2018, 23(9-10):492-511

PubMed: 30027525 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

J Cancer, 2018, 9(12):2061-2071

PubMed: 29937924 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Int J Mol Med, 2018, 41(6):3629-3641

PubMed: 29512701 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):1206-1210

PubMed: 29845253 ( click the link to review the publication )

Anticancer Res, 2018, 38(6):3471-3476

PubMed: 29848699 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35875-35890

PubMed: 30542505 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14017

PubMed: 30228302 ( click the link to review the publication )

Oncotarget, 2018, 9(16):12769-12780

PubMed: 29560108 ( click the link to review the publication )

SLAS Discov, 2018, 23(8):850-861

PubMed: 29742358 ( click the link to review the publication )

J Neurooncol, 2018, 137(3):481-492

PubMed: 29396807 ( click the link to review the publication )
R Soc Open Sci, 2018, 5(12):181303

PubMed: 30662739 ( click the link to review the publication )

Sci Transl Med, 2017, 9(372)

PubMed: 28077684 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8:14294

PubMed: 28220783 ( click the link to review the publication )

Clin Cancer Res, 2017, 10.1158/1078-0432

PubMed: 28073841 ( click the link to review the publication )

EBioMedicine, 2017, 24:43-55

PubMed: 29030058 ( click the link to review the publication )

Plant Physiol, 2017, 173(1):582-599

PubMed: 27879390 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(1):94-107

PubMed: 28848145 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2083-2093

PubMed: 28615297 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2552-2562

PubMed: 28847989 ( click the link to review the publication )

Eur J Med Chem, 2017, 140:1-19

PubMed: 28918096 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(6):670-682

PubMed: 28235899 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

Cell Discov, 2017, 3:16049

PubMed: 28101375 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )

J Biol Chem, 2017, 292(5):1910-1924

PubMed: 28028179 ( click the link to review the publication )

Am J Transl Res, 2017, 9(10):4652-4672

PubMed: 29118925 ( click the link to review the publication )

Am J Transl Res, 2017, 9(3):845-873

PubMed: 28386317 ( click the link to review the publication )

BMC Cell Biol, 2017, 18(1):33

PubMed: 29141582 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(4):386-401

PubMed: 27396604 ( click the link to review the publication )

Oncotarget, 2017, 8(10):16669-16689

PubMed: 28035071 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )
Oncotarget, 2017, 8(19):32117-32133

PubMed: 28389630 ( click the link to review the publication )

Sci Rep, 2017, 7(1):17978

PubMed: 29269934 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )

Oncotarget, 2017, 8(68):112313-112329

PubMed: 29348827 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19738-19759

PubMed: 28160569 ( click the link to review the publication )

Oncotarget, 2017, 8(41):69691-69708

PubMed: 29050234 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 8(59):100326-100338

PubMed: 29245981 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114474-114480

PubMed: 29383095 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19478-19490

PubMed: 28061448 ( click the link to review the publication )

Oncotarget, 2017, 8(54):92926-92942

PubMed: 29190967 ( click the link to review the publication )

Pharmaceuticals (Basel), 2017, 10(3)

PubMed: 29036881 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

Nat Commun, 2016, 7:11389

PubMed: 27091106 ( click the link to review the publication )

Nat Commun, 2016, 7:12674

PubMed: 27624869 ( click the link to review the publication )

J Med Chem, 2016, 59(15):7188-211

PubMed: 27391133 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2135

PubMed: 26962685 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(8):1574-87

PubMed: 26908596 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(12):3400-3411

PubMed: 27768280 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):566-76

PubMed: 27082306 ( click the link to review the publication )
Cell Cycle, 2016, 15(3):413-24

PubMed: 26713495 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:3473-84

PubMed: 27366084 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 475(3):251-6

PubMed: 27233613 ( click the link to review the publication )

Exp Hematol, 2016, 44(4):247-56

PubMed: 26724640 ( click the link to review the publication )

Mol Med Rep, 2016, 14(1):394-8

PubMed: 27177156 ( click the link to review the publication )

Biol Bull, 2016, 231(1):61-72

PubMed: 27638695 ( click the link to review the publication )

Oncotarget, 2016, 7(22):33152-64

PubMed: 27121204 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84718-84735

PubMed: 27713168 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

Mol Cancer, 2015, 14(1):83

PubMed: 25889801 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(9):2292-2300

PubMed: 25848977 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: 25395580 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):527-40

PubMed: 25501809 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):516-26

PubMed: 25501815 ( click the link to review the publication )

J Cell Sci, 2015, 128(20):3769-80

PubMed: 26349807 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: ( click the link to review the publication )

Int J Mol Sci, 2015, 17(1)

PubMed: 26729093 ( click the link to review the publication )

Breast Cancer Res Tr, 2015, 149(3):715-26

PubMed: 25667100 ( click the link to review the publication )

Cell Cycle, 2015, 14(24):3908-19

PubMed: 26697841 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:1555-84

PubMed: 25792811 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:575-601

PubMed: 25632225 ( click the link to review the publication )
BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(34):35247-62

PubMed: 26497213 ( click the link to review the publication )

Clin Cancer Res, 2014, 34(5):2269-74

PubMed: 24778030 ( click the link to review the publication )

Oncogene, 2014, 33(42):4985-96

PubMed: 24166501 ( click the link to review the publication )

Oncogene, 2014, 33(27):3550-60

PubMed: 23955083 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(5):797-811

PubMed: 25074669 ( click the link to review the publication )

Mol Oncol, 2014, 8(8):1419-28

PubMed: 24953013 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2719-2729

PubMed: 25090971 ( click the link to review the publication )

J Transl Med, 2014, 12(1):200

PubMed: 25082261 ( click the link to review the publication )

Mol Carcinog, 2014, 10.1002/mc.22223

PubMed: 25284017 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

FEBS Lett, 2014, 588(14):2198-205

PubMed: 24857377 ( click the link to review the publication )

Chembiochem, 2014, 15(3):443-50

PubMed: 24403173 ( click the link to review the publication )

PLoS One, 2014, 9(12):e113989

PubMed: 25436453 ( click the link to review the publication )

PLoS One, 2014, 9(3):e92402

PubMed: 24642638 ( click the link to review the publication )

PLoS One, 2014, 9(12):e116048

PubMed: 25545367 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101222

PubMed: 24983972 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )
PLoS One, 2014,

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):845-51

PubMed: 25218503 ( click the link to review the publication )

Neurosci Lett, 2014, 583:199-204

PubMed: 25263789 ( click the link to review the publication )

J Pediatr Surg, 2014, 49(1):159-65

PubMed: 24439602 ( click the link to review the publication )

Oncotarget, 2014, 5(10):2947-61

PubMed: 24930769 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6229-42

PubMed: 25153724 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4071-86

PubMed: 24901229 ( click the link to review the publication )

Nat Commun, 2013, 4:2656

PubMed: 24141283 ( click the link to review the publication )

EMBO Mol Med, 2013, 5(1):149-66

PubMed: 23180582 ( click the link to review the publication )

Leukemia, 2013, 27(3):560-8

PubMed: 22940834 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

EMBO Rep, 2013, 14(9):829-36

PubMed: 23887685 ( click the link to review the publication )

Int J Cancer, 2013, 135(3):751-62

PubMed: 24382688 ( click the link to review the publication )

Oral Oncol, 2013, 49(6):551-9

PubMed: 23481312 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(7):1451-9

PubMed: 23597309 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 6):1355-65

PubMed: 23345402 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 9):2102-13

PubMed: 23532825 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1833(10):2220-32

PubMed: 23707954 ( click the link to review the publication )

Epigenetics Chromatin, 2013, 6(1):21

PubMed: 23829974 ( click the link to review the publication )

J Biol Chem, 2013, 289(1):74-88

PubMed: 24273164 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64306

PubMed: 23717592 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

Oncotarget, 2013, 4(1):80-93

PubMed: 23328114 ( click the link to review the publication )
J Biol Chem, 2012, 287(33):27670-81

PubMed: 22753416 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 135(2):433-44

PubMed: 22825030 ( click the link to review the publication )

Cell Cycle, 2012, 11(2):296-309

PubMed: 22214762 ( click the link to review the publication )

Cell Cycle, 2012, 11(13):2567-77

PubMed: 22722494 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30734

PubMed: 22359551 ( click the link to review the publication )

EMBO J, 2011, 30(5):906-19

PubMed: 21297582 ( click the link to review the publication )

Mol Cancer, 2011, 10:131

PubMed: 22011530 ( click the link to review the publication )

J Cell Biol, 2010, 191(7):1315-32

PubMed: 21187329 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):977-84

PubMed: 21072059 ( click the link to review the publication )

ACS Chem Biol, 2010, 5(6):563-76

PubMed: 20426425 ( click the link to review the publication )

Expert Opin Emerg Dr, 2010, 15(4):615-34

PubMed: 20690888 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description

Features

First orally available inhibitor of Aurora A.

Targets

Aurora A ^[1]
(Cell-free assay)

1.2 nM

In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. ^[1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. ^[2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT116	NYnsS\|FxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\wNE42KM7:TR?=	MUe3NkBp	NXXheWlZTE2VTx?=	Mn;4TWM2OD1yLkC0JO69VQ>?	NF7XcJMzPjF\|Nk[4OC=>
LS174T	NHPLRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;mS5F5OC53IN88US=>	NXHhZVd4PzJiaB?=	MnTiSG1UVw>?	NULKcHVCUUN3ME2wMlA2KM7:TR?=	NUC5S3hrOjZzM{[2PFQ>
T84	NVnDcIQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX[wMlUh\|ryP	NH[1V2c4OiCq	MV\EUXNQ	NXG2NllTUUN3ME2wMlA6KM7:TR?=	NIHzT3EzPjF\|Nk[4OC=>
LS180	MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfqNE42KM7:TR?=	MnfqO\|IhcA>?	MlK2SG1UVw>?	MUHJR\|UxRTFizszN	NVXXNnk3OjZzM{[2PFQ>
SW948	NIjNc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrNXI9tOC53IN88US=>	NHzqRZo4OiCq	M13xcmROW09?	NX[yfXE5UUN3ME2xJO69VQ>?	Ml\DNlYyOzZ4OES=
HCT15	NVLtOXhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\qVGwxNjVizszN	MXe3NkBp	MmjDSG1UVw>?	MVvJR\|UxRDBwNDFOwG0>	M1jzSFI3OTN4Nki0
DLD-1	M1fhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYCwMlUh\|ryP	M1XOOlczKGh?	NX\4PJVkTE2VTx?=	MVfJR\|UxRDBwODFOwG0>	NXXYXYVlOjZzM{[2PFQ>
MIP-101	M1y0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\kdGVkOC53IN88US=>	NWHwfFJDPzJiaB?=	MnPGSG1UVw>?	M3LoU2lEPTB;MTFOwG0>	M1rvT\|I3OTN4Nki0
SNU1544	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3i1OlAvPSEQvF2=	M1jJTVczKGh?	NIrVRVBFVVOR	MVnJR\|UxRTFizszN	NXXMSXU2OjZzM{[2PFQ>
OCI-Ly10	MX\DfZRwfG:6aXOgRZN{[Xl?		NXX6[YJYPzJiaB?=	MWPEUXNQ	MWnJR\|UxRTBwMEW4JO69VQ>?	MYeyOVg4QDN\|MR?=
SU-DHL2	M2rDN2N6fG:2b4jpZ{BCe3OjeR?=		MnH3O\|IhcA>?	MmLQSG1UVw>?	M3jQSGlEPTB;MD6wNUDPxE1?	NVXFfFg{OjV6N{izN\|E>
OCI-LY7	NHT4UGNEgXSxdH;4bYMhSXO\|YYm=		MkDQO\|IhcA>?	M4P6NGROW09?	NI\sXHJKSzVyPUCuNFgyKM7:TR?=	M2jCfFI2QDd6M{Ox
SU-DHL6	MmLMR5l1d3SxeHnjJGF{e2G7		NFXFUYM4OiCq	MXPEUXNQ	NHT4e\|dKSzVyPUCuOFgzKM7:TR?=	NG\sZpIzPTh5OEOzNS=>
Jeko-1	M3LtXGN6fG:2b4jpZ{BCe3OjeR?=		M1T3SlczKGh?	NFLtOlFFVVOR	NGLoephKSzVyPUCuNFI6KM7:TR?=	NGnk[ZAzPTh5OEOzNS=>
JVM-2	NH;6W4tEgXSxdH;4bYMhSXO\|YYm=		MUG3NkBp	M1TUS2ROW09?	MUnJR\|UxRTBwMEGg{txO	NXTTS4V2OjV6N{izN\|E>
Rec-1	NUDEW2R3S3m2b4TvfIlkKEG\|c3H5		MXq3NkBp	NV\YXm9pTE2VTx?=	M1jCcGlEPTB;MD6wPFch\|ryP	Ml\zNlU5Pzh\|M{G=
Z-138	NWfJWYRmS3m2b4TvfIlkKEG\|c3H5		NGHI[lg4OiCq	MWfEUXNQ	MYrJR\|UxRTBwMEGzJO69VQ>?	M{XSV\|I2QDd6M{Ox
H9	Mn3RR5l1d3SxeHnjJGF{e2G7		NXrre3JxPzJiaB?=	NVHPWXoyTE2VTx?=	NWDtZZROUUN3ME2wMlYh\|ryP	NYjp[HIxOjV6N{izN\|E>
HH	M3HKSGN6fG:2b4jpZ{BCe3OjeR?=		NFrxcXo4OiCq	MXPEUXNQ	NHjTeWVKSzVyPUCuO{DPxE1?	MVyyOVg4QDN\|MR?=
DND41	MXrDfZRwfG:6aXOgRZN{[Xl?		NVnFS29JPzJiaB?=	MUDEUXNQ	M3TiNGlEPTB;MD6xJO69VQ>?	NUfZXXluOjV6N{izN\|E>
CCL119	Ml21R5l1d3SxeHnjJGF{e2G7		MnKxO\|IhcA>?	NH3hSZhFVVOR	MnzxTWM2OD1yLkC2NkDPxE1?	MUSyOVg4QDN\|MR?=
J.Cam 1.6	NV\ZdFdOS3m2b4TvfIlkKEG\|c3H5		NVzsR3Y5PzJiaB?=	NV\2R4xpTE2VTx?=	NYWwS5hEUUN3ME2wMlExPSEQvF2=	M2PoWFI2QDd6M{Ox
Sup-T1	MWDDfZRwfG:6aXOgRZN{[Xl?		NYrlZodSPzJiaB?=	MoDlSG1UVw>?	NVTUOI1qUUN3ME2yMlE1OiEQvF2=	MlrCNlU5Pzh\|M{G=
Tib 152	NEHMNXREgXSxdH;4bYMhSXO\|YYm=		M4DoRlczKGh?	MV3EUXNQ	NVTucYNXUUN3ME2wMlgh\|ryP	M1rwOVI2QDd6M{Ox
MCF7	MnHBSpVv[3Srb36gRZN{[Xl?	MWS1JO69VQ>?	MnfJNlQhcA>?	NEPweVNFVVOR	MVLJcoR2[2W\|IFeyM20h[XK{ZYP0	MmXjNlU5OzR2MEG=
MDA-MB-231	MmHhSpVv[3Srb36gRZN{[Xl?	M2C5cFUh\|ryP	MViyOEBp	M{\4fGROW09?	M37I[Wlv\HWlZYOgS\|MwVSCjcoLld5Q>	M2f0UlI2QDN2NECx
MCF7	NWj0R5c2TnWwY4Tpc44hSXO\|YYm=	M1XqZ\|Uh\|ryP	NFXXUHkzPCCq	M2rTe2ROW09?	NVW3e2RZTGWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJGNFUzFxQ1TDNi=>	NUD3SY9mOjV6M{S0NFE>
MCF7	Ml2xSpVv[3Srb36gRZN{[Xl?	MWK1JO69VQ>?	MWOyOEBp	MV3EUXNQ	M37ESGRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz	NV;UTFIzOjV6M{S0NFE>
MCF7	MVTGeY5kfGmxbjDBd5NigQ>?	M1PLXVUh\|ryP	MlPFNlQhcA>?	M2rKRWROW09?	NVfoeGxtTGWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJIN6[2yrbjDCNS=>	MWqyOVg{PDRyMR?=
MCF7	M4jaS2Z2dmO2aX;uJGF{e2G7	MoGzOUDPxE1?	M1PxWFI1KGh?	NVnae2JyTE2VTx?=	MVnJcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=>	MYSyOVg{PDRyMR?=
MCF7	MmfNSpVv[3Srb36gRZN{[Xl?	NEHjcJg2KM7:TR?=	MViyOEBp	M3G5fGROW09?	MkjmTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyO{BMcXBz	MmDDNlU5OzR2MEG=
MDA-MB-231	M1PKbmZ2dmO2aX;uJGF{e2G7	M365PVUh\|ryP	MkixNlQhcA>?	NVL4fYVKTE2VTx?=	MWTE[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{	NYnwRY1qOjV6M{S0NFE>
MDA-MB-231	MlnKSpVv[3Srb36gRZN{[Xl?	NVK2[oY1OSEQvF2=	MnnsNlQhcA>?	NYjGOpFSTE2VTx?=	M3PyWWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz	MmmyNlU5OzR2MEG=
MDA-MB-231	M3rYV2Z2dmO2aX;uJGF{e2G7	MX[1JO69VQ>?	NEe0[lMzPCCq	MXfEUXNQ	NU\COo1YTGWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJIN6[2yrbjDCNS=>	M{j6e\|I2QDN2NECx
MDA-MB-231	M3vUbmZ2dmO2aX;uJGF{e2G7	NILZXms2KM7:TR?=	M3nkb\|I1KGh?	NXrLNWc2TE2VTx?=	MmfjTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE>	MVyyOVg{PDRyMR?=
MDA-MB-231	MmS1SpVv[3Srb36gRZN{[Xl?	MYK1JO69VQ>?	M2fuVVI1KGh?	MmHFSG1UVw>?	NF\zOo5KdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG=	MXmyOVg{PDRyMR?=
MDA-MB-231	NHTJRXRHfW6ldHnvckBCe3OjeR?=	MXO1JO69VQ>?	MWqyOEBp	NFvaXHFFVVOR	NHv0SXVKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFU{	M2e4elI2QDN2NECx
MCF7	NGnCb4ZCeG:ydH;zbZMhSXO\|YYm=	MVO1JO69VQ>?	NXj3dYJuOjRiaB?=	M1raUGROW09?	M4XrU2lv\HWlZYOgZZBweHSxdHnjJIRm[XSq	NVL1fYdnOjV6M{S0NFE>
MDA-MB-231	MnrjRZBweHSxc3nzJGF{e2G7	NH6wOGE2KM7:TR?=	NYDodlBJOjRiaB?=	NWDUNXQyTE2VTx?=	MlPBTY5lfWOnczDhdI9xfG:2aXOg[IVifGh?	MmTQNlU5OzR2MEG=
MCF7	NVHR[m9qTnWwY4Tpc44hSXO\|YYm=	MV6xJO69VQ>?	NGjpeXk4OiCq	NWO4RWlTTE2VTx?=	MmK3TY5lfWOnczDheZRweGijZ3njJIRm[XSq	M2THUVI2QDN2NECx
MDA-MB-231	NVrZcJpHTnWwY4Tpc44hSXO\|YYm=	NWX4cVlVOSEQvF2=	MnjhO\|IhcA>?	NYThVXU1TE2VTx?=	NX;Fc2pmUW6mdXPld{BifXSxcHjh[4lkKGSnYYTo	M1nQVlI2QDN2NECx
U-2 OS	MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfnOVAh\|ryP	MnvJNlQhcA>?	NFPFSYtFVVOR	MmK0TWM2OD1zNj62JO69VQ>?	M2\EbFI2Pzl{OEGx
MG-63	NIX5SZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnNOVAh\|ryP	Mmr1NlQhcA>?	MWjEUXNQ	MXTJR\|UxRTlwNTFOwG0>	M2n0TlI2Pzl{OEGx
U-2 OS	NIP4SpVCeG:ydH;zbZMhSXO\|YYm=	NXzocG13PSEQvF2=	NETuRlgzPCCq	NXTUVZJKTE2VTx?=	M2GxUWlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg>	MV:yOVc6OjhzMR?=
MG-63	M3O0NmFxd3C2b4Ppd{BCe3OjeR?=	MYG1JO69VQ>?	MoHBNlQhcA>?	Ml\NSG1UVw>?	NV;HRmZ2UW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>?	NELvfI4zPTd7MkixNS=>
U-2 OS	NFfLUVlHfW6ldHnvckBCe3OjeR?=	NEXxeFc2KM7:TR?=	MmrINlQhcA>?	MWjEUXNQ	NXPjN\|d6WHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq	M3noOVI2Pzl{OEGx
MG-63	Mn7WSpVv[3Srb36gRZN{[Xl?	M{fBTVUh\|ryP	NXXjTpNsOjRiaB?=	M16wVGROW09?	MU\Qdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg>	NInWVIQzPTd7MkixNS=>
PANC-1	NGTObVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHwdYEzPTBizszN	MVKyOEBp	MkjBSG1UVw>?	MV7JR\|UxRTdwMTFOwG0>	MkHwNlU3OzJ{MkW=
BxPC-3	MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonzOVAh\|ryP	NF2yXmwzPCCq	NITKPZhFVVOR	M{fxc2lEPTB;Nj64JO69VQ>?	MmGwNlU3OzJ{MkW=
PANC-1	MoHjSpVv[3Srb36gRZN{[Xl?	MmPxOUDPxE1?	MVOyOEBp	NHqw[nNFVVOR	NFXFNlVKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V?	NVXQdW9qOjV4M{KyNlU>
BxPC-3	M2jKOWZ2dmO2aX;uJGF{e2G7	M4i5PVUh\|ryP	MmH1NlQhcA>?	NWrKVJNwTE2VTx?=	NEHofGtKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V?	NVe5cVRFOjV4M{KyNlU>
PANC-1	M1\IOGZ2dmO2aX;uJGF{e2G7	MV21JO69VQ>?	NH62eoIzPCCq	NV3lSY9LTE2VTx?=	NFnKZm9KdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>?	MWmyOVY{OjJ{NR?=
BxPC-3	MVLGeY5kfGmxbjDBd5NigQ>?	MWK1JO69VQ>?	NV;MUnI6OjRiaB?=	M{nt[mROW09?	M3v3O2lv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp	MlTmNlU3OzJ{MkW=
SKOV3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M12z[FExOCEQvF2=	NX\GfIluOjRiaB?=	MYLEUXNQ	M3LEZmlEPTB;MkCuOFgh\|ryP	NWexNIo3OjV4MkS3OVA>
OVCAR4	NECwb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDUZ4wyODBizszN	NHPjSpkzPCCq	Mmi5SG1UVw>?	Ml[3TWM2OD1{Mj6xN{DPxE1?	MnrxNlU3OjR5NUC=
SKOV3	MXfGeY5kfGmxbjDBd5NigQ>?	NGTaPVM2KM7:TR?=	NFruem04OiCq	M3;ONWROW09?	NXvuU4VFUW6mdXPld{BIOi:PIHHydoV{fA>?	NIWybYkzPTZ{NEe1NC=>
OVCAR4	MYDGeY5kfGmxbjDBd5NigQ>?	NITYTFQ2KM7:TR?=	NYnQ[o5CPzJiaB?=	Mlu3SG1UVw>?	NV71UJBOUW6mdXPld{BIOi:PIHHydoV{fA>?	M2D0b\|I2PjJ2N{Ww
SKOV3	M3uzVmFxd3C2b4Ppd{BCe3OjeR?=	MYG1JO69VQ>?	M2LqeFI1KGh?	NIfnRlhFVVOR	M17pT2lv\HWlZYOgZZBweHSxc3nz	MXKyOVYzPDd3MB?=
OVCAR4	M2Dyd2Fxd3C2b4Ppd{BCe3OjeR?=	NGG1So82KM7:TR?=	MXuyOEBp	NYTlWGpmTE2VTx?=	M2TVPGlv\HWlZYOgZZBweHSxc3nz	M2TGXFI2PjJ2N{Ww
AGS	NY\BTppKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1exdFI2KM7:TR?=	MkXzNlQhcA>?	MnK1SG1UVw>?	MlPGTWM2OD1zOT6wPUDPxE1?	NWj5O2czOjV4MEm5NlM>
NCI-N78	M{DkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYKyOUDPxE1?	NGi1TZMzPCCq	MV;EUXNQ	M1XubWlEPTB;Mk[uN\|Mh\|ryP	NXHCeJU{OjV4MEm5NlM>
AGS	MonaRZBweHSxc3nzJGF{e2G7	NHjPbYk2KM7:TR?=	MUSyOEBp	NH36cmpFVVOR	NX\pNmhuUW6mdXPld{BieG:ydH;zbZM>	NXnw[VNsOjV4MEm5NlM>
NCI-N78	NWjqSYo2SXCxcITvd4l{KEG\|c3H5	NITu[FI2KM7:TR?=	M1LUO\|I1KGh?	MkDRSG1UVw>?	NYfwfZVxUW6mdXPld{BieG:ydH;zbZM>	NH\aUXczPTZyOUmyNy=>
AGS	MljzSpVv[3Srb36gRZN{[Xl?	MkLnOUDPxE1?	MWiyOEBp	NGjSSYdFVVOR	NYD2VI4zUW6mdXPld{B1cGViYYX0c5Bp[We7	MlnGNlU3ODl7MkO=
NCI-N78	NWi3c204TnWwY4Tpc44hSXO\|YYm=	M{SzVlUh\|ryP	NFLlT3EzPCCq	MojrSG1UVw>?	NIjYSVJKdmS3Y3XzJJRp\SCjdYTvdIhi\3l?	NHeyNHczPTZyOUmyNy=>
HSC-3	NFS2V5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUKxJO69VQ>?	MmLYOFghcA>?		NEjPPFBKSzVyPUCuOVQh\|ryP	NXrUVmtyOjV\|Nk[xOFM>
GB30	M37tTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzNNUDPxE1?	M1zrcFch\A>?	NH;FTJVFVVOR	MYjJR\|UxRTBwMEGxJO69VQ>?	MVKyOVExPjR{OB?=
GB9	NHSzOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3vOZcyKM7:TR?=	NV63T4h2PyCm	NXjRWmJETE2VTx?=	M3zuPWlEPTB;MD6wNlQh\|ryP	MnrPNlUyODZ2Mki=
GB169	NU\2dmo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLoNUDPxE1?	NHu3Z\|M4KGR?	M2DtWGROW09?	NFLodYtKSzVyPUCuNFMzKM7:TR?=	MVWyOVExPjR{OB?=
T24	MYLGeY5kfGmxbjDBd5NigQ>?	NVG1VJJoOSEQvF2=	NEK5W3c1QCCq	M2PQOmROW09?	MUjJcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2	MXuyN\|QxOzZ\|Mx?=
RT4	MoLvSpVv[3Srb36gRZN{[Xl?	MmGxNUDPxE1?	NVG0RY5mPDhiaB?=	NF7xRZRFVVOR	MmT0TY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dB?=	Mn\SNlM1ODN4M{O=
UM-UC-3	MYLGeY5kfGmxbjDBd5NigQ>?	NV;4WYY3OSEQvF2=	MYm0PEBp	MYTEUXNQ	NWr0ZlVMUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=>	MVuyN\|QxOzZ\|Mx?=
T24	NX;uZ2pJSXCxcITvd4l{KEG\|c3H5	MmPqN{4yPiEQvF2=	NIDicVI6PiCq	MkPkSG1UVw>?	MnTDTWM2OD1yLkCzNFYh\|ryP	MYWyN\|QxOzZ\|Mx?=
RT4	MnvKRZBweHSxc3nzJGF{e2G7	NYD0SZVlOy5zNjFOwG0>	M1zxTVk3KGh?	NYS4TIFUTE2VTx?=	M2PxRmlEPTB;MD6xNVk5KM7:TR?=	MoTlNlM1ODN4M{O=
UM-UC-3	M13VfGFxd3C2b4Ppd{BCe3OjeR?=	MYSzMlE3KM7:TR?=	M1H2OVk3KGh?	NV:1UI4yTE2VTx?=	NV\pNlR{UUN3ME2wMlA1PDlizszN	NHnNcWMzOzRyM{[zNy=>
OVCAR-5	NYrob5kzTnWwY4Tpc44hSXO\|YYm=	NVHwXJVPPTBibl2=			M4\ocGlvcGmkaYTzJINmdGxibXnndoF1cW:w	NUjWcm01OjN\|M{SzNlc>
SKOV3ip2	MmLUSpVv[3Srb36gRZN{[Xl?	MoTJOVAhdk1?			MXLJcohq[mm2czDj[YxtKG2rZ4LheIlwdg>?	MWWyN\|M{PDN{Nx?=
S462	NWPUNphTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLoNVAxKM7:TR?=	NEj0fW04OiCq	MW\EUXNQ	MWjBeJRmdnWjdHXzJINmdGxiZ4Lve5Rp	NHvQb3EzOzN{OEGxOC=>
2884	M3LpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUixNFAh\|ryP	NXTTVXNNPzJiaB?=	NWLuW\|VXTE2VTx?=	MYrBeJRmdnWjdHXzJINmdGxiZ4Lve5Rp	M2j6S\|I{OzJ6MUG0
2885	NGDFZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;UZZgyODBizszN	NXPycoZPPzJiaB?=	NGK3bI5FVVOR	NGHCSJdCfHSnboXheIV{KGOnbHyg[5Jwf3Sq	MnexNlM{OjhzMUS=
CRL-2396	NWLue48yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfFOlBuOTByIN88US=>		NH7jem54[XSnch?=	NIi2bWdKSzVyPUCuNFkzKM7:TR?=	NWPnZ5ZPOjNzNUO1NlQ>
TIB-48	Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjhOpFyOTByIN88US=>		MlvYe4F1\XJ?	NVPkSohUUUN3ME2wMlA5QCEQvF2=	NE\xenkzOzF3M{WyOC=>
CRL-2396	M13LUWN6fG:2b4jpZ{BCe3OjeR?=	NX\aSmp6OSEQvF2=	Mn6wOFghcA>?	NF;BSY14[XSnch?=	NHHJRmNKdmS3Y3XzJIFxd3C2b4Ppdy=>	M1LLO\|I{OTV\|NUK0
TIB-48	NYXUbnEyS3m2b4TvfIlkKEG\|c3H5	NYf1SWMzOSEQvF2=	NEXRS2g1QCCq	NYjMNGxVf2G2ZYK=	MWTJcoR2[2W\|IHHwc5B1d3Orcx?=	MY[yN\|E2OzV{NB?=
AGS	Mmm5R5l1d3SxeHnjJGF{e2G7	MVywMlUh\|ryP	Mle3NlQhcA>?	NGewR5lFVVOR	NWfNXmhnTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy=	NEPRXnozOjl5Mk[xNS=>
FLO-1	NYnGfXdlS3m2b4TvfIlkKEG\|c3H5	MkW2NE42KM7:TR?=	MX:yOEBp	NHLqPGtFVVOR	M{LnOmRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu	NWr5NVhQOjJ7N{K2NVE>
OE33	MU\DfZRwfG:6aXOgRZN{[Xl?	NGf3N2oxNjVizszN	M17WWVI1KGh?	MYfEUXNQ	Ml[zSIVkemWjc3XzJINmdGxic4Xyeol3[Wx?	Ml7XNlI6PzJ4MUG=
SKLMS	MV\DfZRwfG:6aXOgRZN{[Xl?	M3P6Vlc2KG6P	MYi5OkBp		MV3JcoR2[2W\|IHHwc5B1d3Orcx?=	NFTJcWEzOjh{MUm5Oy=>
Leio285	NX3q[oZlS3m2b4TvfIlkKEG\|c3H5	MojUO\|Uhdk1?	NYnGTIJDQTZiaB?=		M1rwe2lv\HWlZYOgZZBweHSxc3nz	Mk\ONlI5OjF7OUe=
Mes-Sa	M1T1dGN6fG:2b4jpZ{BCe3OjeR?=	M2\vOlc2KG6P	NV3a[2JqQTZiaB?=		MWDJcoR2[2W\|IHHwc5B1d3Orcx?=	MnHWNlI5OjF7OUe=
DAOY	NGfubHFEgXSxdH;4bYMhSXO\|YYm=	M{Xpd\|ExKM7:TR?=	MlvEO\|IhcA>?	NUfyc5h5TE2VTx?=	NYK5dVFLUUN3ME2wMlA1KM7:TR?=	NF71NpAzOjZ4OUOzOS=>
IMR32	M2LJdGN6fG:2b4jpZ{BCe3OjeR?=	NVraWXB1OTBizszN	NYizPJN5PzJiaB?=	NEXxWlZFVVOR	NFjqdW5KSzVyPUCuNFMh\|ryP	NXzkXoF4OjJ4NkmzN\|U>
Molt-4	NELz[YxEgXSxdH;4bYMhSXO\|YYm=	MYOxNEDPxE1?	MlrvO\|IhcA>?	NXnJU4VzTE2VTx?=	MmXFTWM2OD1yLkCyJO69VQ>?	NWLPd49oOjJ4NkmzN\|U>
MOLM-13	M1rzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXsN{DPxE1?	NVO2XIZ2PzJiaB?=		M3u2[2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	NVvIXZlEOjJ2OEiyOFk>
HL-60	NGjXdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWCzJO69VQ>?	MlrLO\|IhcA>?		M37D[GRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	M1f6b\|IzPDh6MkS5
MV4-11	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXTZWQ{KM7:TR?=	MVq3NkBp		NFr2RWhFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	MUCyNlQ5QDJ2OR?=
SKM-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\SN{DPxE1?	MoezO\|IhcA>?		M4Syd2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	NFfFW2wzOjR6OEK0PS=>
SH2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk[3N{DPxE1?	MmPpO\|IhcA>?		M1fUdWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	M2P6SFIzPDh6MkS5
NOMO-1	M3yyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\XNFMh\|ryP	MX63NkBp		NHjZe\|NFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	M{jEb\|IzPDh6MkS5
OCL-AML2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWmzJO69VQ>?	M172eVczKGh?		M3KxWmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	M2jMSlIzPDh6MkS5
PL-21	NEK2O5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnINW4yOyEQvF2=	NIDJTWk4OiCq		NHfpVo1FcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	MkS5NlI1QDh{NEm=
KG-1	MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEGzbGQ{KM7:TR?=	Mli1O\|IhcA>?		M33CNWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	NX7yd4Q2OjJ2OEiyOFk>
A172	MnPIR5l1d3SxeHnjJGF{e2G7	NF;adW0yODBizszN	MWGyOEBp	MUnEUXNQ	NEi1ZlZKSzVyPUCuNVIxKM7:TR?=	MVOyNlI4PDN7OR?=
U87	MXjDfZRwfG:6aXOgRZN{[Xl?	M2Oyc\|ExOCEQvF2=	M1fqcFI1KGh?	MnrlSG1UVw>?	MUTJR\|UxRTBwMUC1JO69VQ>?	NWDyRnhNOjJ{N{SzPVk>
U251	MlK2R5l1d3SxeHnjJGF{e2G7	NUPwO\|UxOTByIN88US=>	MViyOEBp	NGnkS5ZFVVOR	MVvJR\|UxRTBwMUCwJO69VQ>?	NX;WXHc3OjJ{N{SzPVk>
T98	M1:5[WN6fG:2b4jpZ{BCe3OjeR?=	MYixNFAh\|ryP	MU[yOEBp	MWHEUXNQ	M2XQcGlEPTB;MD6xNlUh\|ryP	MmrRNlIzPzR\|OUm=
LN18	Ml64R5l1d3SxeHnjJGF{e2G7	MYSxNFAh\|ryP	NXfNWWFDOjRiaB?=	M2rLVGROW09?	NGjLTpdKSzVyPUCuNlExKM7:TR?=	NH;nW4wzOjJ5NEO5PS=>
LN443	MYXDfZRwfG:6aXOgRZN{[Xl?	NYPTWW5wOTByIN88US=>	NU\N[FB7OjRiaB?=	MX7EUXNQ	M3TWZmlEPTB;MD6yNlAh\|ryP	M3TKe\|IzOjd2M{m5
HF66	NV3wZYsxS3m2b4TvfIlkKEG\|c3H5	NECzUHEyODBizszN	NYK5e5dUOjRiaB?=	MUDEUXNQ	MVPJR\|UxRTBwMkK1JO69VQ>?	M4LwSVIzOjd2M{m5
HF2303	M1T4cGN6fG:2b4jpZ{BCe3OjeR?=	NEmyRmQyODBizszN	Ml3CNlQhcA>?	MWnEUXNQ	MVXJR\|UxRTBwME[wJO69VQ>?	MkflNlIzPzR\|OUm=
HF2359	MVTDfZRwfG:6aXOgRZN{[Xl?	MnqzNVAxKM7:TR?=	NFnzN4gzPCCq	NXXTcnZ7TE2VTx?=	M3:0RmlEPTB;MD6wOlAh\|ryP	MnyxNlIzPzR\|OUm=
HF2414	MnvyR5l1d3SxeHnjJGF{e2G7	NHHsZlIyODBizszN	NH;qSnEzPCCq	NWnPcZpiTE2VTx?=	NHrMVI1KSzVyPUCuNFgxKM7:TR?=	MUCyNlI4PDN7OR?=
A-673	Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDXNVAh\|ryP	MkjwPVYhcA>?	MXjEUXNQ	MoP3TWM2OD1yLkCzNkDPxE1?	M4TxbFIyPDR6NUmx
TC-32	NInVWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzFXo8yOCEQvF2=	NHvMPHU6PiCq	NELmVHFFVVOR	NELhfJpKSzVyPUCuNFM6KM7:TR?=	M1OxfFIyPDR6NUmx
TC-71	M3LuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnMNVAh\|ryP	MXm5OkBp	NFPWV29FVVOR	MXHJR\|UxRTBwMUCyJO69VQ>?	NX3MNHlEOjF2NEi1PVE>
SK-N-MC	NGDoTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnUfW4yOCEQvF2=	NX7NOndJQTZiaB?=	NVryU25qTE2VTx?=	MnywTWM2OD1yLkC3NkDPxE1?	NX\UN\|FJOjF2NEi1PVE>
CHLA-9	NH2x[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{exNVExKM7:TR?=	NGLkUHA6PiCq	NYPWVW4yTE2VTx?=	MVjJR\|UxRTBwMEG4JO69VQ>?	MUWyNVQ1QDV7MR?=
CHLA-10	M{HHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\oRVExKM7:TR?=	MUe5OkBp	NVvadIlOTE2VTx?=	MnezTWM2OD1yLkC2NEDPxE1?	M1vMRlIyPDR6NUmx
CHLA-25	NVvvenFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXK5cnNtOTBizszN	NVr6e3hYQTZiaB?=	NW\zSHZoTE2VTx?=	M4jkb2lEPTB;MD6xOlgh\|ryP	MljsNlE1PDh3OUG=
CHLA-32	NEfLe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDPNVAh\|ryP	NIn0XIU6PiCq	NHP3RYhFVVOR	NGLPd3RKSzVyPUCuNVM3KM7:TR?=	M{LBUlIyPDR6NUmx
CHLA-56	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml25NVAh\|ryP	M{nOVFk3KGh?	NV\3TWs4TE2VTx?=	NEP5NIdKSzVyPUGwJO69VQ>?	M{PUSFIyPDR6NUmx
CHLA-258	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV72OFRmOTBizszN	NVP0dZRPQTZiaB?=	MoDmSG1UVw>?	MWHJR\|UxRTBwMUOyJO69VQ>?	M1zmVFIyPDR6NUmx
COG-E-352	NUWzNHJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLJZXYyOCEQvF2=	MWC5OkBp	MlLXSG1UVw>?	M2f0NmlEPTB;MD6wOFMh\|ryP	NEjzfnUzOTR2OEW5NS=>
CHLA-90	Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDzeHdjOTBizszN	MY[5OkBp	MkjDSG1UVw>?	NWDFO3ZvUUN3ME2wMlA3OSEQvF2=	M2\YUlIyPDR6NUmx
CHLA-119	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml2yNVAh\|ryP	M{nQeVk3KGh?	M37qZmROW09?	NUf3TJBGUUN3ME2wMlAzOiEQvF2=	M{XQWFIyPDR6NUmx
CHLA-122	NE\iUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFuxVZMyOCEQvF2=	NVjiT3l5QTZiaB?=	Mn\TSG1UVw>?	NUS2UJB2UUN3ME2wMlAyQSEQvF2=	NUnrXGg3OjF2NEi1PVE>
CHLA-136	M1rJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\BXIg5OTBizszN	MmXQPVYhcA>?	M4S3NWROW09?	NHjESZBKSzVyPUCuNFM6KM7:TR?=	M2jmOlIyPDR6NUmx
CHLA-140	NH7hVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTJXlQyOCEQvF2=	M3qxVVk3KGh?	NHvhc3RFVVOR	NWnMbXRPUUN3ME2wMlAzPiEQvF2=	MV2yNVQ1QDV7MR?=
LA-N-6	NFTZPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXv5dWkxOTBizszN	MlrHPVYhcA>?	M4XoXmROW09?	NEnRWoRKSzVyPUCuNFU1KM7:TR?=	M1TmSVIyPDR6NUmx
NB-1643	NFOzPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWqxNEDPxE1?	MWO5OkBp	NUDGUmdjTE2VTx?=	MoXvTWM2OD1yLkCzO{DPxE1?	NGLvZYozOTR2OEW5NS=>
NB-EBc1	M3;PVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEn5b2syOCEQvF2=	NV7rTXlzQTZiaB?=	M2L1NWROW09?	MWTJR\|UxRTBwMEWwJO69VQ>?	MW[yNVQ1QDV7MR?=
SK-N-BE-1	MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU[xNEDPxE1?	M1P3O\|k3KGh?	NXHpe\|JITE2VTx?=	NHu3XmNKSzVyPUCuNFI5KM7:TR?=	NGTtb3ozOTR2OEW5NS=>
SK-N-BE-2	M{PxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\YdmF[OTBizszN	NIjrPIk6PiCq	MWHEUXNQ	M37ZOGlEPTB;MD6wN\|Yh\|ryP	M4KwXlIyPDR6NUmx
SMS-KAN	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jvbFExKM7:TR?=	NXHFO\|VIQTZiaB?=	NXHQ[4xlTE2VTx?=	M{XqZmlEPTB;MD6wN\|Qh\|ryP	NIXsbYYzOTR2OEW5NS=>
SMS-KANR	M{PLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmWxNVAh\|ryP	M3HvSlk3KGh?	MVvEUXNQ	MXLJR\|UxRTBwMEK2JO69VQ>?	M1HnPFIyPDR6NUmx
SMS-KCN	NFT5[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvZNVAh\|ryP	MV[5OkBp	NYXiPIhtTE2VTx?=	MUfJR\|UxRTBwMEG5JO69VQ>?	NYjFOIVCOjF2NEi1PVE>
SMS-KCNR	M3;Qc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zMSlExKM7:TR?=	NEnYT3Y6PiCq	M1HqNWROW09?	NGrMZ4NKSzVyPUCuNFExKM7:TR?=	MVGyNVQ1QDV7MR?=
SMS-LHN	M1vGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWmxNEDPxE1?	M1zYSVk3KGh?	MULEUXNQ	NV:3[lJCUUN3ME2wMlA{OiEQvF2=	M{C3NlIyPDR6NUmx
SMS-MSN	NUXzeZNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYWxNEDPxE1?	MmfsPVYhcA>?	NXXtZoxPTE2VTx?=	MlzRTWM2OD1yLkCyNkDPxE1?	MnPKNlE1PDh3OUG=
SMS-SAN	NEHYRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DoNFExKM7:TR?=	Mny2PVYhcA>?	NY[5bpcxTE2VTx?=	MlSwTWM2OD1yLkCyNEDPxE1?	MWiyNVQ1QDV7MR?=
Granta-4	MXTDfZRwfG:6aXOgRZN{[Xl?	M3TRT\|ExKM7:TR?=	MWC3JIQ>		NWTSZ3RxUUN3ME2wMlA1OCEQvF2=	NIf5eJczOTJ7MUi2Oy=>
DB	NIfIc2tEgXSxdH;4bYMhSXO\|YYm=	MmDJNVAh\|ryP	NYnTU3dqPyCm		M4PSbmlEPTB;MD6wOFIh\|ryP	M1nHclIyOjlzOE[3
RL	NXrwflNOS3m2b4TvfIlkKEG\|c3H5	MW[xNEDPxE1?	M1j3c\|ch\A>?		M1vxdWlEPTB;MD6wNVUh\|ryP	MlrNNlEzQTF6Nke=
K562	NH\nZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV6xNEDPxE1?	M4TTcVk3KGh?		NEfOemxKSzVyPUCuNFg4KM7:TR?=	NHTwUmszOTB7MU[zNy=>
LAMA-84	M1ywTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfrNVAh\|ryP	MUW5OkBp		NFn6VXFKSzVyPUCuNFU4KM7:TR?=	NYDaN3JyOjFyOUG2N\|M>
MM15	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrsOEDPxE1?	NE\ZWIY4OiCq	MWPEUXNQ	MXrJR\|UxRTBwMUOg{txO	MX6yNFM5Ojh2NB?=
OPM1	MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfM[Y9vPCEQvF2=	MXy3NkBp	NHviTnVFVVOR	NIixeHNKSzVyPUCuNFMh\|ryP	MlfXNlA{QDJ6NES=
RPM1	NGXjdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLYOEDPxE1?	MoTiO\|IhcA>?	MkHtSG1UVw>?	MX3JR\|UxRTFyLkOyJO69VQ>?	M1\5RlIxOzh{OES0
INA6	NEfJRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PtSFQh\|ryP	NFraRYU4OiCq	M{Phe2ROW09?	NGDld3dKSzVyPUCuNFAzKM7:TR?=	NETu[\|AzODN6Mki0OC=>
OPM2	NEnSOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7FOEDPxE1?	Mm\SO\|IhcA>?	MlTHSG1UVw>?	NVm3[YJxUUN3ME20MlM4KM7:TR?=	M1;5NVIxOzh{OES0
MM1R	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIflZlg1KM7:TR?=	NUHaVJN[PzJiaB?=	NIn6NIpFVVOR	MnXITWM2OD1zLk[4JO69VQ>?	MXmyNFM5Ojh2NB?=
DOX40	NXL5eYY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjMbnI1KM7:TR?=	MkD4O\|IhcA>?	NVnubYRxTE2VTx?=	MUXJR\|UxRTVwNEig{txO	NFnDZpAzODN6Mki0OC=>
LR5	MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDrb\|M1KM7:TR?=	M1fVbVczKGh?	M{m3cGROW09?	NVTnbVB5UUN3ME2yMlU{KM7:TR?=	NF6zdpEzODN6Mki0OC=>
U266	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3ud2o1KM7:TR?=	MYW3NkBp	M4TTNGROW09?	MVPJR\|UxRTFwNEOg{txO	NFzOOoczODN6Mki0OC=>
RD	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmf6NVAh\|ryP	NF\aVVM6PiCq		NG\BXpdKSzVyPUCuNlI5KM7:TR?=	NWfmd4p6OjBzMEizN\|g>
Rh41	NUjXTZJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWWxNEDPxE1?	NGfDOJA6PiCq		MmHJTWM2OD1yLkC5NEDPxE1?	MlHNNlAyODh\|M{i=
Rh30	NVLkfXgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUexNEDPxE1?	MkH5PVYhcA>?		NELudmpKSzVyPUCuNlMxKM7:TR?=	NV6xdpNXOjBzMEizN\|g>
BT-12	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXYNVAh\|ryP	M2PVNVk3KGh?		NFzRfpJKSzVyPUCuNFYxKM7:TR?=	M1zkcFIxOTB6M{O4
CHLA-266	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXLeHIyOCEQvF2=	MXe5OkBp		M1vVbmlEPTB;MD6wO\|Ih\|ryP	NF\yVIkzODFyOEOzPC=>
TC-71	M37iWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnzdYhyOTBizszN	M4rFclk3KGh?		MU\JR\|UxRTBwMUCyJO69VQ>?	NGLQdFQzODFyOEOzPC=>
SJ-GBM2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTJdHMzOTBizszN	NWrDRpJ3QTZiaB?=		M37xXGlEPTB;MD6wOVAh\|ryP	Mn7BNlAyODh\|M{i=
NALM-6	NVnpdVNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlr2NVAh\|ryP	NUfNNVJlQTZiaB?=		M2rZTWlEPTB;MD6wOlIh\|ryP	NHfxZokzODFyOEOzPC=>
COG-LL-317	NUn0eYNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHH4SYgyOCEQvF2=	NHrQPHM6PiCq		NX3TcnhPUUN3ME2wMlA1PyEQvF2=	MnPnNlAyODh\|M{i=
RS4-11	NE\PdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HadFExKM7:TR?=	M17Ke\|k3KGh?		Ml31TWM2OD1yLkCxPEDPxE1?	M{fUeFIxOTB6M{O4
MOLT-4	M4Psfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF6yN2syOCEQvF2=	MkXtPVYhcA>?		MVLJR\|UxRTBwMEK2JO69VQ>?	MYWyNFExQDN\|OB?=
CCRF-CEM	NYnRS3pzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;ONVAh\|ryP	NHTyTIE6PiCq		NIfJeY5KSzVyPUCuNFk1KM7:TR?=	NEHyTJIzODFyOEOzPC=>
Kasumi-1	M4TXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:yc5BPOTBizszN	MYO5OkBp		MV7JR\|UxRTBwMUCzJO69VQ>?	MUiyNFExQDN\|OB?=
Karpas-299	NXTYcHhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33zZlExKM7:TR?=	MXK5OkBp		NH\SS\|FKSzVyPUCuNFM5KM7:TR?=	NFX3ZZAzODFyOEOzPC=>
Ramos-RA1	NETrSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjQXlAyOCEQvF2=	Mk\tPVYhcA>?		MXrJR\|UxRTBwMUK3JO69VQ>?	NWiwXlBjOjBzMEizN\|g>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AURKA(T288) / p-EIF4E(S209) / c-Myc; PubMed: 28073841 Clin Cancer Res Inhibition of AURKA with alisertib downregulated p-EIF4E (S209) and c-MYC protein levels as assayed by Western blotting. phospho-Aurora A / Aurora B; PubMed: 22863010 Cell MLN8237differentially inhibited phosphorylation of Aurora kinases. CMK cells were incubated with 0.1 µM paclitaxel for 18 hr, then DMSO or MLN8237 was added and incubated for 2 hr. The degree of phosphorylation of the Aurora kinases in each sample was determined by Western blot. H3S10P / H3K27me2 / H3K27me3 / H3K9me2 / H3AcK / H4K16Ac; PubMed: 29477140 Mol Cells THP-1 cells were treated with alisertib or DMSO for 48 h. The levels of histone modifications were detected by western blot analysis with the indicated antibodies. H3 was used as a loading control.	28073841 22863010 29477140
Growth inhibition assay	Cell viability; PubMed: 25632225 Drug Des Devel Ther PANC-1 and BxPC-3 cells were treated with ALS at concentrations ranging from 0.1 μM to 50 μM for 24 hours. The viability of PANC-1 and BxPC-3 cells determined by MTT assay. ALS, alisertib.	25632225
Immunofluorescence	acetylated α-tubulin / γ-tubulin; PubMed: 29401581 FASEB J Representative immunofluorescence (IF) image and graph in human PKD1-mutant WT9-7, WT9-12 cells or hTERT-RPE1 (RPE1) cells after 2 hours treatment with vehicle, ganetespib , or alisertib to inhibit AURKA, or combination of alisertib and ganetespib. acetylated α-tubulin (red); γ-tubulin (green); DAPI (blue). Scale bars, 5 μm. E-cadherin / β-catenin / vimentin / p-SMAD5; PubMed: 23334326 Oncogene Immunofluorescence analysis of CD24 (-/low) cells treated with1 μM MLN8237 for 48 and 72 h showing reversion of EMT. E-cadherin and p-SMAD5 were labeled in red, β-catenin and vimentin were labeled in green, and DNA was labeled in blue with Hoechst dye. Centrin-2 / tubulin; PubMed: 30899434 Oncotarget Following inhibition of Aurora A kinase activity with 100 nM alisertib, cells with two or excess centrosomes similarly exhibit disorganized mitotic spindles. Cells with extra centrosomes are efficiently clustered into bipolar spindles prior to anaphase onset while those with supernumerary centrosomes undergo multipolar mitoses. Centrin-2, a marker of centrioles is shown in green, tubulin in red, and chromatin in blue. AurA inhibitor: alisertib. phospho-Aurora A(T288); PubMed: 20382844 Blood MM1.S cells were treated with DMSO or MLN8237 (0.5μM) for 24 hours and then stained with anti-phospho (Thr288)-Aurora-A kinase antibody (red), αtubulin (green), and DNA (blue). Overlapping localization is shown in the merged images. Arrow indicates Aurora-A autophosphorylation on Thr288 in the centrosome (original magnification ×40). Magnified single mitotic cell image is shown in the right panel.	29401581 23334326 30899434 20382844

In vivo

MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Aurora A radioactive Flashplate enzyme assay: Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-³³P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:^[2]	- Collapse Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266 Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 24, 48, and 72 hours Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using ³[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells Dosages: ~30 mg/kg/day Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	27 mg/mL (52.03 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+30% PEG300+5%Tween-80+ddH2O For best results, use promptly after mixing.	8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Alisertib (MLN8237) SDF

Molecular Weight	518.92
Formula	C₂₇H₂₀ClFN₄O₄
CAS No.	1028486-01-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	COC1=C(C(=CC=C1)F)C2=NCC3=C(N=C(NC4=CC(=C(C=C4)C(O)=O)OC)N=C3)C5=C2C=C(Cl)C=C5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02812056	Withdrawn	Drug: Alisertib\|Drug: TAK-228	Malignant Neoplasms of Digestive Organs\|Malignant Neoplasms of Female Genital Organs\|Malignant Neoplasms of Lip Oral Cavity and Pharynx\|Malignant Neoplasms of Male Genital Organs	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals Inc.	September 2016	Phase 1
NCT02719691	Recruiting	Drug: Alisertib\|Drug: MLN0128	Metastatic Breast Cancer\|Solid Tumors	University of Colorado Denver	May 13 2016	Phase 1
NCT02367352	Terminated	Drug: Alisertib\|Drug: Paclitaxel	Advanced Solid Tumors\|Ovarian Cancer\|Small Cell Lung Cancer	Millennium Pharmaceuticals Inc.\|Takeda	March 19 2015	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the suggested formulation of this compound for mouse injection(i.p.)?
Answer:
It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Pan Aurora Kinase Inhibitor

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
Pan Aurora Kinase Inhibitor

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
Most Potent Aurora Kinase Inhibitor

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
Aurora Kinase Inhibitor in Clinical Trial

VX-680 (Tozasertib, MK-0457) : Phase II for Advanced Non-Small Cell Lung Cancer (NSCLC).
Classic Aurora Kinase Inhibitor

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

Related Aurora Kinase Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007), is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).
Barasertib (AZD1152-HQPA)

Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Tozasertib (VX-680, MK-0457)

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with K_i_app of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.
Danusertib (PHA-739358)

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.
ZM 447439

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

Features:An Aurora selective ATP-competitive inhibitor.
MLN8054

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.
MK-5108 (VX-689)

MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.
Aurora A Inhibitor I (TC-S 7010)

Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.

Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

Alisertib (MLN8237)